PHAR Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

16.890

Open

16.800

VWAP

16.54

Vol

39.02K

Mkt Cap

1.18B

Low

16.230

Amount

645.55K

EV/EBITDA(TTM)

23.58

Total Shares

69.67M

EV

1.12B

EV/OCF(TTM)

--

P/S(TTM)

2.94

Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

Show More

Events Timeline

(ET)

2026-03-24

11:10:00

Pharming Group's Joenja Approved in Japan for APDS Treatment

2026-02-02 (ET)

2026-02-02

09:00:00

U.S. Stock Futures Weaker, Tech Stocks Under Pressure

2026-02-01 (ET)

2026-02-01

21:30:00

Ford in Talks with Xiaomi for U.S. Market Entry

2026-02-01

18:50:00

Pharming Group Receives Complete Response Letter from FDA for Joenja Application

2025-12-18 (ET)

2025-12-18

10:40:00

Clearmind Completes Second Cohort Enrollment for CMND-100 Trial

2025-12-03 (ET)

2025-12-03

07:00:00

Pharvaris Announces RAPIDe-3 Pivotal Data Confirming Deucrictibant's Treatment Potential

News

seekingalpha

03-27seekingalpha

Pharming Group Receives Positive Opinion for Joenja

Newsfilter

03-27Newsfilter

Pharming's Joenja® Receives Positive EMA Opinion for APDS Treatment

NASDAQ.COM

03-24NASDAQ.COM

Japan Approves Joenja for APDS Treatment

seekingalpha

03-12seekingalpha

Pharming Group Reports Strong Q4 2025 Earnings Growth

seekingalpha

03-12seekingalpha

Pharming Reports Q4 2025 Earnings with Revenue Growth

Globenewswire

03-03Globenewswire

Pomerantz LLP Investigates Pharming Group for Securities Fraud

2 Analyst Rating

Wall Street analysts forecast PHAR stock price to rise

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

37.00

Averages

39.50

High

42.00

Current: 0.000

Low

37.00

Averages

39.50

High

42.00

Oppenheimer

Oppenheimer

Outperform

to

Outperform

downgrade

$42 -> $41

AI Analysis

2026-03-13

Reason

Oppenheimer

Oppenheimer

Price Target

$42 -> $41

AI Analysis

2026-03-13

downgrade

Outperform

to

Outperform

Reason

Oppenheimer lowered the firm's price target on Pharming to $41 from $42 and keeps an Outperform rating on the shares. The firm notes the company reported solid Q4 and full-year results. Joenja exceeded Oppenheimer's expectations for Q4, while Ruconest growth continues to grow despite the launch of oral competitor, which the firm believes is driven by its strong efficacy and differentiated patient population. Oppenheimer is encouraged by continued execution on both the commercial and development front with multiple potential approvals for Joenja in 2026 likely.

Guggenheim

Debjit Chattopadhyay

Buy

maintain

$32 -> $39

2025-12-04

Reason

Guggenheim

Debjit Chattopadhyay

Price Target

$32 -> $39

2025-12-04

maintain

Buy

Reason

Guggenheim analyst Debjit Chattopadhyay raised the firm's price target on Pharvaris to $39 from $32 and keeps a Buy rating on the shares after the company shared that its RAPIDe-3 trial hit on the primary and all 11 secondary endpoints. Post the RAPIDe-3 topline data readout, the firm is increasing its global peak sales estimate for deucrictibant to $1.65B from $1.4B during 2037.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PHAR

Unlock Now

Valuation Metrics

The current forward P/E ratio for Pharming Group NV (PHAR.O) is 102.04, compared to its 5-year average forward P/E of -49.45. For a more detailed relative valuation and DCF analysis to assess Pharming Group NV's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-49.45

Current PE

102.04

Overvalued PE

223.01

Undervalued PE

-321.91

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

142.26

Current EV/EBITDA

33.95

Overvalued EV/EBITDA

401.92

Undervalued EV/EBITDA

-117.41

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

2.71

Current PS

3.03

Overvalued PS

3.27

Undervalued PS

2.15

Financials

AI Analysis

Annual

Quarterly

Whales Holding PHAR

Trading Trends

People Also Watch

Frequently Asked Questions

What is Pharming Group NV (PHAR) stock price today?

The current price of PHAR is 16.51 USD — it has decreased -2.42

What is Pharming Group NV (PHAR)'s business?

Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

What is the price predicton of PHAR Stock?

Wall Street analysts forecast PHAR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHAR is39.50 USD with a low forecast of 37.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Pharming Group NV (PHAR)'s revenue for the last quarter?

Pharming Group NV revenue for the last quarter amounts to NaN USD, decreased

What is Pharming Group NV (PHAR)'s earnings per share (EPS) for the last quarter?

Pharming Group NV. EPS for the last quarter amounts to USD, decreased

How many employees does Pharming Group NV (PHAR). have?

Pharming Group NV (PHAR) has 382 emplpoyees as of April 03 2026.

What is Pharming Group NV (PHAR) market cap?

Today PHAR has the market capitalization of 1.18B USD.